Copyright Reports & Markets. All rights reserved.

Global Sacituzumab Govitecan Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Sacituzumab Govitecan Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 180mg / vial
    • 1.3.3 200mg / vial
  • 1.4 Market Analysis by Production Technology
    • 1.4.1 Overview: Global Sacituzumab Govitecan Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
    • 1.4.2 Innovator
    • 1.4.3 Generic
  • 1.5 Market Analysis by Sales Channels
    • 1.5.1 Overview: Global Sacituzumab Govitecan Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
    • 1.5.2 Hospital
    • 1.5.3 Retail
    • 1.5.4 Online
  • 1.6 Market Analysis by Antibody Type
    • 1.6.1 Overview: Global Sacituzumab Govitecan Consumption Value by Antibody Type: 2021 Versus 2025 Versus 2032
    • 1.6.2 Monoclonal Antibody
    • 1.6.3 Polyclonal Antibody
  • 1.7 Market Analysis by Application
    • 1.7.1 Overview: Global Sacituzumab Govitecan Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.7.2 Advanced or Metastatic Solid Tumors
    • 1.7.3 Metastatic Triple-Negative Breast Cancer
    • 1.7.4 Metastatic Urothelial Carcinoma
    • 1.7.5 Others
  • 1.8 Global Sacituzumab Govitecan Market Size & Forecast
    • 1.8.1 Global Sacituzumab Govitecan Consumption Value (2021 & 2025 & 2032)
    • 1.8.2 Global Sacituzumab Govitecan Sales Quantity (2021-2032)
    • 1.8.3 Global Sacituzumab Govitecan Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Gilead Sciences
    • 2.1.1 Gilead Sciences Details
    • 2.1.2 Gilead Sciences Major Business
    • 2.1.3 Gilead Sciences Sacituzumab Govitecan Product and Services
    • 2.1.4 Gilead Sciences Sacituzumab Govitecan Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Gilead Sciences Recent Developments/Updates

3 Competitive Environment: Sacituzumab Govitecan by Manufacturer

  • 3.1 Global Sacituzumab Govitecan Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Sacituzumab Govitecan Revenue by Manufacturer (2021-2026)
  • 3.3 Global Sacituzumab Govitecan Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Sacituzumab Govitecan by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Sacituzumab Govitecan Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Sacituzumab Govitecan Manufacturer Market Share in 2025
  • 3.5 Sacituzumab Govitecan Market: Overall Company Footprint Analysis
    • 3.5.1 Sacituzumab Govitecan Market: Region Footprint
    • 3.5.2 Sacituzumab Govitecan Market: Company Product Type Footprint
    • 3.5.3 Sacituzumab Govitecan Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Sacituzumab Govitecan Market Size by Region
    • 4.1.1 Global Sacituzumab Govitecan Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Sacituzumab Govitecan Consumption Value by Region (2021-2032)
    • 4.1.3 Global Sacituzumab Govitecan Average Price by Region (2021-2032)
  • 4.2 North America Sacituzumab Govitecan Consumption Value (2021-2032)
  • 4.3 Europe Sacituzumab Govitecan Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Sacituzumab Govitecan Consumption Value (2021-2032)
  • 4.5 South America Sacituzumab Govitecan Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Sacituzumab Govitecan Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Sacituzumab Govitecan Sales Quantity by Type (2021-2032)
  • 5.2 Global Sacituzumab Govitecan Consumption Value by Type (2021-2032)
  • 5.3 Global Sacituzumab Govitecan Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Sacituzumab Govitecan Sales Quantity by Application (2021-2032)
  • 6.2 Global Sacituzumab Govitecan Consumption Value by Application (2021-2032)
  • 6.3 Global Sacituzumab Govitecan Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Sacituzumab Govitecan Sales Quantity by Type (2021-2032)
  • 7.2 North America Sacituzumab Govitecan Sales Quantity by Application (2021-2032)
  • 7.3 North America Sacituzumab Govitecan Market Size by Country
    • 7.3.1 North America Sacituzumab Govitecan Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Sacituzumab Govitecan Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Sacituzumab Govitecan Sales Quantity by Type (2021-2032)
  • 8.2 Europe Sacituzumab Govitecan Sales Quantity by Application (2021-2032)
  • 8.3 Europe Sacituzumab Govitecan Market Size by Country
    • 8.3.1 Europe Sacituzumab Govitecan Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Sacituzumab Govitecan Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Sacituzumab Govitecan Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Sacituzumab Govitecan Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Sacituzumab Govitecan Market Size by Region
    • 9.3.1 Asia-Pacific Sacituzumab Govitecan Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Sacituzumab Govitecan Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Sacituzumab Govitecan Sales Quantity by Type (2021-2032)
  • 10.2 South America Sacituzumab Govitecan Sales Quantity by Application (2021-2032)
  • 10.3 South America Sacituzumab Govitecan Market Size by Country
    • 10.3.1 South America Sacituzumab Govitecan Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Sacituzumab Govitecan Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Sacituzumab Govitecan Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Sacituzumab Govitecan Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Sacituzumab Govitecan Market Size by Country
    • 11.3.1 Middle East & Africa Sacituzumab Govitecan Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Sacituzumab Govitecan Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Sacituzumab Govitecan Market Drivers
  • 12.2 Sacituzumab Govitecan Market Restraints
  • 12.3 Sacituzumab Govitecan Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Sacituzumab Govitecan and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Sacituzumab Govitecan
  • 13.3 Sacituzumab Govitecan Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Sacituzumab Govitecan Typical Distributors
  • 14.3 Sacituzumab Govitecan Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Sacituzumab Govitecan market size was valued at US$ 144 million in 2025 and is forecast to a readjusted size of US$ 639 million by 2032 with a CAGR of 15.6% during review period.
    Sacituzumab Govitecan is a Trop‑2‑targeted antibody‑drug conjugate (ADC) composed of a humanized anti‑Trop‑2 monoclonal antibody, a hydrolyzable CL2A linker, and SN‑38, a cytotoxic topoisomerase I inhibitor. The drug specifically binds to the Trop‑2 antigen on the surface of tumor cells, is internalized into cells, and releases the cytotoxic payload to precisely kill tumor cells. It is mainly indicated for the treatment of solid tumors such as metastatic triple‑negative breast cancer and metastatic urothelial carcinoma. Featuring strong targeting, high antitumor activity and a wide therapeutic window, it is an important targeted therapeutic agent in the field of advanced solid tumors.In 2025, global Sacituzumab Govitecan (Trodelvy) production reached approximately 1.6 million vials.
    Sacituzumab Govitecan, the world’s first Trop‑2‑targeted antibody‑drug conjugate (ADC), occupies an important market position in refractory solid tumors such as triple‑negative breast cancer. It has remarkable clinical value and has become the standard second‑line treatment for advanced triple‑negative breast cancer. It also demonstrates favorable efficacy in HR‑positive, HER2‑negative breast cancer and urothelial carcinoma. Globally, the drug has been approved in 59 countries and regions. With its unique mechanism of action and excellent clinical data, it continues to drive the expansion of the ADC market. In the domestic market, Sacituzumab Govitecan has been included in many commercial insurance and inclusive medical insurance programs, gradually improving drug accessibility. With the successive launch of domestic Trop‑2 ADCs, market competition has become increasingly fierce. However, its first‑mover advantage, clinical recognition and potential for indication expansion still support its market competitiveness. In the future, with the approval of first‑line indications, the advancement of combination therapies and accelerated medical insurance access, Sacituzumab Govitecan is expected to further expand its market share and reshape the treatment landscape of solid tumors.
    This report is a detailed and comprehensive analysis for global Sacituzumab Govitecan market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Sacituzumab Govitecan market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Sacituzumab Govitecan market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Sacituzumab Govitecan market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Sacituzumab Govitecan market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Sacituzumab Govitecan
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Sacituzumab Govitecan market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gilead Sciences, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Sacituzumab Govitecan market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    180mg / vial
    200mg / vial
    Market segment by Production Technology
    Innovator
    Generic
    Market segment by Sales Channels
    Hospital
    Retail
    Online
    Market segment by Antibody Type
    Monoclonal Antibody
    Polyclonal Antibody
    Market segment by Application
    Advanced or Metastatic Solid Tumors
    Metastatic Triple-Negative Breast Cancer
    Metastatic Urothelial Carcinoma
    Others
    Major players covered
    Gilead Sciences
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Sacituzumab Govitecan product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Sacituzumab Govitecan, with price, sales quantity, revenue, and global market share of Sacituzumab Govitecan from 2021 to 2026.
    Chapter 3, the Sacituzumab Govitecan competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Sacituzumab Govitecan breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Sacituzumab Govitecan market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Sacituzumab Govitecan.
    Chapter 14 and 15, to describe Sacituzumab Govitecan sales channel, distributors, customers, research findings and conclusion.

    Buy now